According to the Zhitong Finance App, Yipinhong (300723.SZ) issued an announcement. Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for paramivir injections approved and issued by the State Drug Administration. This medicine is used to treat influenza A or B Currently, peramivir injections have been included in the national medical insurance category B catalogue. The company's approved peramivir injection was registered as a chemical in category 3, which is considered to have passed the consistency evaluation. According to data from the Mi Intranet, the sales scale of peramivir in Chinese cities and county-level public hospitals in 2025 is about 809 million yuan.

According to the Zhitong Finance App, Yipinhong (300723.SZ) issued an announcement. Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for paramivir injections approved and issued by the State Drug Administration. This medicine is used to treat influenza A or B Currently, peramivir injections have been included in the national medical insurance category B catalogue. The company's approved peramivir injection was registered as a chemical in category 3, which is considered to have passed the consistency evaluation. According to data from the Mi Intranet, the sales scale of peramivir in Chinese cities and county-level public hospitals in 2025 is about 809 million yuan.